Scarica l'app Stockscreener
5.28
2.92%
0.15
Dopo l'orario di chiusura:
5.36
0.08
+1.52%
Precedente Chiudi:
$5.13
Aprire:
$5.13
Volume 24 ore:
4.52M
Relative Volume:
2.78
Capitalizzazione di mercato:
$489.52M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+3.33%
1M Prestazione:
+11.16%
6M Prestazione:
+35.04%
1 anno Prestazione:
+247.37%
Intervallo 1D:
$4.955
$5.47
Intervallo di 1 settimana:
$4.78
$5.50
Portata 52W:
$1.48
$5.98
Atyr Pharma Inc Stock (ATYR) Company Profile
Nome
Atyr Pharma Inc
Settore
Industria
Telefono
(858) 731-8389
Indirizzo
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Confronta ATYR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
5.28 | 489.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-18 | Iniziato | Leerink Partners | Outperform |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Iniziato | Wells Fargo | Overweight |
| 2024-09-05 | Iniziato | Jefferies | Buy |
| 2023-07-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-10 | Iniziato | Laidlaw | Buy |
| 2020-08-17 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Iniziato | ROTH Capital | Buy |
| 2020-03-02 | Iniziato | Oppenheimer | Outperform |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2016-12-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Iniziato | Citigroup | Neutral |
| 2015-06-01 | Iniziato | Citigroup | Buy |
| 2015-06-01 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
With 70% ownership, aTyr Pharma, Inc. (NASDAQ:ATYR) boasts of strong institutional backing - Yahoo Finance
Bank of America Corp DE Makes New $330,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - MarketBeat
Cantor Fitzgerald Comments on Atyr PHARMA FY2026 Earnings - MarketBeat
Two Sigma Investments LP Takes Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
91,224 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Bank of America Corp DE - Defense World
Atyr PHARMA (NASDAQ:ATYR) Stock Price Up 6.1%Here's Why - MarketBeat
Cantor Fitzgerald Estimates Atyr PHARMA FY2026 Earnings - Defense World
aTyr: Promising Data But Cash May Be An Issue (NASDAQ:ATYR) - Seeking Alpha
Squarepoint Ops LLC Invests $96,000 in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Two Sigma Advisers LP Makes New $44,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Millennium Management LLC Makes New Investment in Atyr PHARMA INC (NASDAQ:ATYR) - MarketBeat
H.C. Wainwright reaffirms aTyr Pharma stock with a $35 price target - Investing.com UK
Atyr PHARMA (NASDAQ:ATYR) Receives Buy Rating from HC Wainwright - Defense World
aTyr Pharma reports positive interim results for SSc-ILD treatment By Investing.com - Investing.com South Africa
aTyr Pharma Announces Findings from Interim Analysis of - GlobeNewswire
ATYR Stock Update: HC Wainwright Reiterates 'Buy' Rating with $3 - GuruFocus
ATYR Stock Update: HC Wainwright Reiterates 'Buy' Rating with $35 Price Target | ATYR Stock News - GuruFocus
aTyr Pharma reports positive interim results for SSc-ILD treatment - Investing.com Australia
aTyr Pharma (ATYR) Reports Promising Interim Results for Efzofitimod | ATYR Stock News - GuruFocus
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) - GlobeNewswire
Millennium Management LLC Takes $1.33 Million Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Breakthrough: aTyr's New Drug Shows Promising Results in 75% of Severe Scleroderma Patients - Stock Titan
aTyr Pharma (ATYR) Scheduled for Key Presentation in New York | - GuruFocus
aTyr Pharma (ATYR) Scheduled for Key Presentation in New York | ATYR Stock News - GuruFocus
aTyr Pharma stock soars to 52-week high of $4.66 By Investing.com - Investing.com Nigeria
Atyr PHARMA INC (NASDAQ:ATYR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
182,625 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Northern Trust Corp - Defense World
Woodline Partners LP Purchases New Position in Atyr PHARMA INC (NASDAQ:ATYR) - MarketBeat
Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
High Growth Tech Stocks in the US to Watch This May 2025 - Yahoo Finance
Group One Trading LLC Takes $26,000 Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Jane Street Group LLC Invests $720,000 in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma’s SWOT analysis: biotech firm’s stock poised for potential breakthrough - Investing.com India
aTyr Pharma’s SWOT analysis: biotech firm’s stock poised for potential breakthrough By Investing.com - Investing.com South Africa
aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential - Insider Monkey
aTyr Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
aTyr Pharma Announces Triple Conference Schedule: RBC, Jefferies, and Piper Sandler Healthcare Events Coming Up - Stock Titan
aTyr Pharma (ATYR) Highlights Efzofitimod Research at ATS 2025 | ATYR Stock News - GuruFocus
aTyr Pharma (ATYR) Highlights Efzofitimod Research at ATS 2025 | - GuruFocus
aTyr Pharma (ATYR) Receives Steady 'Buy' Rating from HC Wainwright | ATYR Stock News - GuruFocus
Such Is The Power Of Atyr Pharma Inc (NASDAQ: ATYR) - Stocksregister
aTyr Pharma Presents Three Posters on Efzofitimod at the - GlobeNewswire
Breakthrough Phase 3 Trial Reveals 158,900 Patients Could Benefit from New Sarcoidosis Treatment - Stock Titan
Balyasny Asset Management L.P. Buys Shares of 44,310 Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference - The Manila Times
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rul - GuruFocus
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Dimensional Fund Advisors LP Makes New $881,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Atyr Pharma Inc Azioni (ATYR) Dati Finanziari
Non sono disponibili dati finanziari per Atyr Pharma Inc (ATYR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Atyr Pharma Inc Azioni (ATYR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
| SCHIMMEL PAUL | Director |
Jul 24 '24 |
Buy |
1.93 |
52,300 |
101,038 |
413,023 |
| SCHIMMEL PAUL | Director |
Jul 22 '24 |
Buy |
1.74 |
41,052 |
71,500 |
354,075 |
| SCHIMMEL PAUL | Director |
Jul 23 '24 |
Buy |
1.82 |
6,648 |
12,075 |
360,723 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):